BIOLASE ANNOUNCES THE DEVELOPMENT OF A STRATEGIC PLAN TO PARTNER WITH POST-GRADUATE DENTAL SPECIALTY PROGRAMS IN THE UNITED STATES
Waterlase Dental Laser Adoption Set to Grow Among Dental Residency Programs
LAKE FOREST, Calif., August 31, 2022 /PRNewswire/ — BIOLASEInc. (NASDAQ: BIOL), the global leader in dental lasers, today announced a strategic plan to partner with postgraduate dental specialty programs across North Americato expose new dentists to the benefits of Waterlase technology.
In the United States, there are approximately 700 postgraduate residency programs. The programs range from one to four years and are general and specialty dentistry programs.
“If you know the technology adoption lifecycle, we’re in the early adoption phase,” said John Casciano, Special Markets Sales Director for BIOLASE. “We believe investing in postgraduate programs will accelerate the adoption curve and be mutually beneficial. Residents will learn the benefits of all tissue laser technologies in dentistry while providing the latest in patient care.”
“During the second quarter of 2022, we integrated our Waterlase lasers into several postgraduate programs and expect to continue this growth and integration over the next few years. There is a great appetite among dental residents to use cutting-edge technology in This is the first generation of dentists brought up with new technologies as a normal part of their daily lives,” Casciano said.
dr. Sam Lowprofessor emeritus of University of Florida, accept. He added, “The introduction and reinforcement of technology during postgraduate education is critical to the adoption of laser dentistry by the next generation of dentists. Technology was a valuable part of dentistry when I started practicing, but technology is mandatory for today’s modern dental practitioner.
The Waterlase dental laser offers a range of benefits to dentists and their patients, from faster procedures to less invasive treatment options. Educating postgraduate residents on the benefits of dental lasers is part of BIOLASE’s ongoing efforts to help improve patient experience and outcomes, and to significantly raise awareness of the benefits of laser dentistry.
BIOLASE is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. BIOLASE products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 302 patented and 31 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products offer advanced technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s main products are dental laser systems that perform a wide range of dental procedures, including cosmetic and complex surgical applications. From 1998 to December 31, 2021, BIOLASE has sold more than 43,300 laser systems in more than 80 countries around the world. The laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase Express™ and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseincInstagram at www.instagram.com/waterlase_laserdentistry and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding expected revenues and revenue growth of BIOLASE and its beliefs about their financial resources. Forward-looking statements can be identified by the use of words such as “may”, “could”, “will”, “intend”, “should”, “could”, “may”, “should”, “continue”, “expect”, “believe”, “anticipate”, “estimate”, “predict”, “prospects”, “potential”, “plan”, “seek” and similar expressions and variations or the negatives of these terms or other comparable terms terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations based on a number of factors. These factors include, but are not limited to, the coronavirus (COVID-19) and the effects of the outbreak and actions taken with respect thereto, adverse changes in general economic and market conditions, competitive factors, including , but not limited to, pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing growth of the business and the other risks and uncertainties which are described in the “Risk Factors” section of BIOLASE’s most recent annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE assumes no responsibility to revise or update forward-looking statements.
For more information, please contact:
EVC Group LLC
Michel Polyviou / Todd Kehrli
[email protected] / [email protected]
SOURCE BIOLASE, Inc.